Secondary non‐invasive prenatal screening for fetal trisomy: an effectiveness study in a public health setting
Authors:
- Gavin P GuyGGGavin P Guy
- Basky ThilaganathanBTBasky Thilaganathan
- the SAFE test collaborativeTCthe SAFE test collaborative
Open Access
- 13 August 2020
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (2) , 440-446
Abstract
Objective: To evaluate the effectiveness of secondary screening using non‐invasive prenatal testing (NIPT) in a routine NHS setting including test performance, turn‐around times (TATs) and no‐call (failure to obtain result) rates. To examine the influence of maternal and fetal characteristics on test performance.Design: Retrospective cohort.Setting: London teaching hospital.Sample: A total of 8651 pregnancies undergoing screening for fetal trisomy using NIPT provided by an NHS cell‐free DNA screening laboratory – the SAFE laboratory.Methods: Screening test evaluation and TATs. Univariate and multivariate logistic regression analysis to identify significant predictors of no‐call results and reported by low fetal fraction (40%) and processing failure.Main outcome measures: Test performance, TATs and no‐call rates, factors affecting no‐call results.Results: Average TAT was 4.0 days (95% CI 4.0–4.2 days). Test sensitivities for trisomies 21 and 13/18 were 98.9% (95% CI 95.9–99.9%) and 90.4% (95% CI 80.0–96.8%), respectively. The overall no‐call rate was 32/8651 (0.37%, 95% CI 0.26–0.52%). The overall risk of a no‐call result was influenced by gestational age, dichorionic twin pregnancy, history of malignancy and pregnancies affected by trisomy 13/18, but not by maternal weight or use of low‐molecular‐weight heparin.Conclusions: High‐throughput NIPT can be effectively embedded into a public health NHS setting. TATs of 4 days and no‐calls of <0.5% were well within clinically desirable tolerances. Gestational age, maternal weight, assisted reproductive techniques, use of low‐molecular‐weight heparin and past history of malignancy did not have major impacts on test no‐call rates and should not constitute reasons for withholding the option of NIPT from women.Tweetable Turn‐around times of 4 days, no‐call (test failure) rates of 0.37% and highly accurate NIPT can be successfully embedded in the NHS.Keywords
This publication has 17 references indexed in Scilit:
- Non‐invasive cell‐free fetal DNA testing for aneuploidy: multicenter study of 31 515 singleton pregnancies in southeastern ChinaUltrasound in Obstetrics & Gynecology, 2019
- ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practiceUltrasound in Obstetrics & Gynecology, 2017
- The IONA® Test: Development of an Automated Cell-Free DNA-Based Screening Test for Fetal Trisomies 13, 18, and 21 That Employs the Ion Proton Semiconductor Sequencing PlatformFetal Diagnosis and Therapy, 2017
- Practice Bulletin No. 163Obstetrics & Gynecology, 2016
- Clinical experience with single‐nucleotide polymorphism‐based non‐invasive prenatal screening for 22q11.2 deletion syndromeUltrasound in Obstetrics & Gynecology, 2016
- Clinical evaluation of the IONA test: a non‐invasive prenatal screening test for trisomies 21, 18 and 13Ultrasound in Obstetrics & Gynecology, 2015
- IONA test for first‐trimester detection of trisomies 21, 18 and 13Ultrasound in Obstetrics & Gynecology, 2015
- Cell-free DNA Analysis for Noninvasive Examination of TrisomyNew England Journal of Medicine, 2015
- Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocolBMC Pregnancy and Childbirth, 2014
- Clinical utility of noninvasive fetal trisomy (NIFTY) test – early experienceThe Journal of Maternal-Fetal & Neonatal Medicine, 2012